Note: This document has been translated from the Japanese original for reference purpose only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



For Immediate Release:

November 25, 2025

Name of listed company: Taki Chemical Co., Ltd.

Representative: Katsuhiko Taki, Representative Director, President Code number: 4025 (Prime Market of Tokyo Stock Exchange)

Inquiries to: Osamu Okamoto, General Manager,

General Affairs & Personnel Department Tel: +81-(0)79-437-6002

Notice regarding recognition of gain on sale of Investment Securities (Extraordinary Income)

Taki Chemical Co., Ltd. (the "Company") hereby announces that we have recorded a gain on sale of investment securities (extraordinary income) due to the sale of a portion of our cross-shareholdings and pure investment shares. Details are as follows.

1. Reason for the sale

From the perspective of improving capital efficiency and strengthening governance, we have thoroughly examined the purpose, the benefits and risks associated with our holding shares and determined that certain cross-shareholdings lack sufficient significance for continued ownership. Accordingly, we are reducing such cross-shareholdings in a phased manner.

- 2. Details of the shares of subsidiaries and associates and investment securities sold
 - (1) Type of assets sold

Seven investment securities held by the Company

(2) Period

February to October 2025

(3) Gain on sale of investment securities

¥584 million

3. Outlook

The gain on the sale of investment securities mentioned above will be recorded as extraordinary income in the non-consolidated financial statements for the fourth quarter of the fiscal year ending December 2025. In the consolidated financial statements for the fiscal year ending December 2025, we will record a total of ¥690

million, including the gains on the sale of investment securities held by our group companies, as extraordinary income.

Additionally, we have incorporated such gain on the sale of investment securities into the financial results forecasts for the fiscal year ending December 2025, as announced in the "Notice regarding upward revision of earnings and dividend forecasts, and acquisition of own shares" dated August 7, 2025.

End of Document –